GLP-1 Insurance Coverage and Medicare Advantage Plans in 2026: What Men Need to Know Before Their First Fill

If you or someone you know is counting on Medicare to help cover the cost of semaglutide or tirzepatide in 2026, the numbers may come as a shock. A landmark study published in the American Journal of Health-System Pharmacy found that the rate of first-fill out-of-pocket costs exceeding $600 for GLP-1 receptor agonists jumped from roughly 40–45% to over 80% in standalone Medicare Part D prescription drug plans between 2024 and 2025 — and that trajectory isn’t reversing in 2026. For men who have worked hard to manage their metabolic health, diabetes, or obesity, this isn’t just a policy footnote. It’s a financial gut-punch that can derail treatment before it even begins.

Understanding how Medicare Advantage plans are restructuring their benefit design — and what your real costs are likely to be — has become essential knowledge for anyone using or considering GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound under Medicare coverage. This article breaks down exactly what changed, why it happened, and what practical steps you can take to protect both your wallet and your health outcomes.

The Inflation Reduction Act Was Supposed to Help — So What Went Wrong?

The Inflation Reduction Act (IRA) was heralded as a major win for Medicare beneficiaries. Its headline reforms — eliminating the notorious “donut hole” coverage gap and capping annual out-of-pocket drug costs at $2,000 — sounded like unambiguous good news. For men managing expensive chronic conditions, the promise of a hard ceiling on yearly drug spending felt like real relief. But as with most policy reforms, the devil revealed itself in the details of insurer response.

Zhang, Blyumin, Qu, and colleagues conducted a retrospective comparative analysis using publicly available Centers for Medicare and Medicaid Services datasets, comparing Medicare Part D plan structures from January 2024 to January 2025. What they found was a deliberate and systematic restructuring of how plans distribute cost burden. Rather than absorbing higher costs themselves, insurers shifted the financial weight toward the beginning of the benefit year — exactly when patients are most likely to walk away from a prescription they can’t immediately afford.

In Medicare Advantage Prescription Drug plans specifically, mean annual deductibles surged from $98.70 in 2024 to $249.00 in 2025 — a 152% increase in a single year. Standalone prescription drug plans saw deductibles climb from an average of $384.70 to $454.00 over the same period. Simultaneously, the use of co-insurance-style cost sharing — where you pay a percentage of a drug’s list price rather than a fixed dollar co-pay — exploded for tier 3 medications, rising from just 6.3% of MAPD plans in 2024 to 38.1% in 2025. For an expensive injectable like semaglutide or tirzepatide, the difference between a $50 co-pay and 25% co-insurance on a $1,000+ drug is not trivial. It is the difference between filling your prescription and not.

The researchers concluded plainly: Medicare Part D plans in 2025 were strategically designed to increase beneficiaries’ financial responsibilities via higher deductibles, increased co-insurance cost sharing, and restricted formulary coverage. Yes, the annual out-of-pocket cap theoretically protects you over a full year — but if the first fill costs $800 and you weren’t expecting it, that protection does nothing for you in January when you can’t pay.

GLP-1 Coverage in 2026: What Medicare Advantage Plans Actually Cover

The coverage picture for GLP-1 receptor agonists under Medicare is complicated by a fundamental legal distinction that men pursuing these medications need to understand clearly. Medicare Part D has historically covered GLP-1 medications approved for type 2 diabetes management — drugs like semaglutide injected subcutaneously under the brand name Ozempic, or tirzepatide as Mounjaro. Coverage for the obesity-specific indications of the same or similar drugs has been far more restricted.

The same study noted that while overall GLP-1 coverage across plans decreased, coverage did expand modestly for preferred drugs including subcutaneous semaglutide and tirzepatide — suggesting that insurers are not blocking access entirely, but rather repositioning these drugs in ways that maximize cost-sharing exposure for the patient. Being on a “covered” formulary tier means very little if that coverage comes with a $500 deductible before any benefit kicks in and a 30% co-insurance structure afterward.

For 2026, men navigating Medicare Advantage plans should approach this process with a forensic level of attention. During Medicare’s Annual Enrollment Period — which runs from October 15 through December 7 each year — you have the ability to compare plans using the Medicare Plan Finder tool at medicare.gov. The critical variables to examine are not just whether your specific GLP-1 medication appears on a plan’s formulary, but which tier it sits on, what the deductible structure is for that tier, and whether cost sharing is expressed as a fixed co-pay or a percentage co-insurance. A plan that advertises low premiums but structures GLP-1 coverage under a high-deductible co-insurance tier may cost you significantly more over the course of a year than a higher-premium plan with a predictable flat co-pay.

It’s also worth understanding that Medicare Advantage plans are offered by private insurers who contract with Medicare, and their formularies can change year to year. A drug covered at a manageable cost in 2025 may be moved to a different tier — or dropped from the formulary entirely — in 2026. Always verify your specific medication’s coverage status for the upcoming plan year, and never assume continuity from one year to the next.

For men who do not yet qualify for Medicare and are accessing GLP-1 medications through employer-sponsored or marketplace insurance, the landscape is different but equally worth monitoring. Many commercial insurers have added prior authorization requirements, step therapy protocols requiring that patients try older medications first, and BMI or comorbidity thresholds before approving coverage. Working with your prescribing physician to document medical necessity thoroughly — including relevant diagnoses, lab values, and prior treatment history — is the single most effective strategy for navigating prior authorization successfully.

Protecting Your Access: Practical Strategies That Actually Work

The research makes one thing unmistakably clear: the structural changes baked into Medicare Part D for 2025 and beyond are not accidental. They are the insurance industry’s calculated adaptation to policy reform, and they are likely to persist or intensify in 2026 as plans continue to optimize their benefit designs around the new regulatory environment. That means the burden of navigation falls squarely on you as the patient.

Start by requesting a full year cost estimate from any plan you’re considering during enrollment. Medicare’s Plan Finder tool provides this functionality — it allows you to input your specific medications and see projected annual costs based on the plan’s formulary structure. This estimated annual figure, rather than the monthly premium alone, should drive your plan selection if you are taking or planning to take an expensive medication like a GLP-1 agonist.

If you are already enrolled in a Medicare Advantage plan and facing a first-fill cost that you cannot sustain, manufacturer patient assistance programs are worth investigating immediately. Novo Nordisk and Eli Lilly both maintain savings programs for their GLP-1 products, though eligibility criteria and availability for Medicare patients vary and have changed over time. Your prescribing physician’s office or a hospital-based social worker can often help identify which programs currently apply to your specific situation — this is a resource many men leave entirely untapped.

For men who are pre-Medicare and working with commercial insurance, the appeals process is more accessible than most people realize. If a prior authorization is denied, you have the right to appeal — and a physician-supported appeal with thorough clinical documentation succeeds at a meaningful rate. Ask your doctor’s office explicitly whether they have staff experienced in managing prior authorizations for GLP-1 medications, because this has become a specialty skill in its own right at many practices.

It’s also worth noting that the GLP-1 medication landscape is evolving. Oral semaglutide (Rybelsus) for type 2 diabetes is already available, and oral formulations for weight management are in development and regulatory review. As more formulations enter the market and as patent landscapes shift, generic or biosimilar versions of currently expensive injectables may become available within the next several years — potentially reshaping the affordability picture in ways that current insurance restructuring cannot fully anticipate.

And for the men who are pursuing fat loss, metabolic health, and body recomposition outside of pharmaceutical interventions entirely — the principles remain the same regardless of whether a medication is in the picture. A high-protein diet, consistent resistance training, adequate sleep, and managed stress address the same biological systems that GLP-1 medications target. The research on GLP-1 receptor agonists is compelling, but the medication is a tool, not a replacement for the fundamentals that support long-term health.

The Takeaway

The Inflation Reduction Act’s $2,000 annual out-of-pocket cap is a real benefit — but it is not the protection many Medicare beneficiaries expected it to be for high-cost medications like GLP-1 agonists. Insurers have responded by front-loading costs through higher deductibles and co-insurance structures, meaning the annual ceiling may never be reached by patients who simply cannot afford the first fill. The data shows first-fill costs exceeding $600 now affect more than 80% of standalone Part D plan enrollees seeking GLP-1 medications — a number that should alarm anyone who cares about medication adherence and health equity among older men.

Going into 2026, the most important thing you can do is treat your Medicare plan selection with the same rigor you’d apply to any major financial decision. Compare total projected annual costs, not premiums. Verify formulary placement and cost-sharing structure for your specific medication. Know your appeal rights and manufacturer support options. And if the system makes it difficult — which it increasingly does — find a physician or patient advocate who knows how to navigate it. Your health is worth the effort.